Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs) EQUITY
$146.38
neg -5.90
-3.90%
Today's Range: 146.03 - 149.30 | AMGN Avg Daily Volume: 2,739,700
Last Update: 06/24/16 - 3:59 PM EDT
Volume: 4,894,177
YTD Performance: -6.20%
Open: $147.20
Previous Close: $152.27
52 Week Range: $130.09 - $181.81
Oustanding Shares: 751,217,078
Market Cap: 112,539,830,455
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 4
Moderate Buy 2 2 2 2
Hold 9 9 9 9
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.30 2.30 2.30 2.30
Latest Dividend: 1.00
Latest Dividend Yield: 2.67%
Dividend Ex-Date: 05/13/16
Price Earnings Ratio: 13.91
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
13.91 15.90 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
2.36% -5.83% 54.93%
GROWTH 12 Mo 3 Yr CAGR
Revenue 8.00 0.20 0.08
Net Income 34.50 0.60 0.17
EPS 35.20 0.60 0.18
Earnings for AMGN:
EBITDA 10.63B
Revenue 21.66B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $2.74 $2.77 $11.16 $12.06
Number of Analysts 10 9 12 12
High Estimate $2.97 $3.19 $12.21 $13.54
Low Estimate $2.60 $2.65 $10.80 $11.16
Prior Year $2.57 $2.72 $10.38 $11.16
Growth Rate (Year over Year) 6.77% 1.96% 7.51% 8.03%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Bret Jensen

 | Jun 20, 2016 | 12:00 PM EDT

Large biotech stocks are still at their cheapest valuations since 2011.

By

Gary Morrow

 | May 25, 2016 | 3:22 PM EDT

A fresh rally leg could be on the way if AMGN can remain above the $152 area in the near term. 

By

Bret Jensen

 | May 24, 2016 | 11:00 AM EDT

Keep cash on hand and be ready for oportunities as they arise.

By

Skip Raschke

 | May 24, 2016 | 8:30 AM EDT

I prefer a bullish synthetic call.

By

Carolyn Boroden

 | May 23, 2016 | 8:00 AM EDT

But there is no guarantee that it will fully play out.

By

Bret Jensen

 | May 17, 2016 | 10:00 AM EDT

It is hard to see much growth in the market overall, until earnings growth returns.

By

Carolyn Boroden

 | May 16, 2016 | 9:00 AM EDT

The S&P 500 is testing the neckline of a head-and-shoulders pattern.

By

Mark Sebastian

 | May 10, 2016 | 12:48 PM EDT

The cream of the biotech crop seems to have found a floor after a rough set of earnings.

By

Bret Jensen

 | May 9, 2016 | 11:08 AM EDT

And it's hard to get excited about the second quarter, too.

By

Carolyn Boroden

 | May 8, 2016 | 10:30 PM EDT

We also look at Amgen and the biotech index.

.... that Monday is a total bloodbath.

I was going to publish a thought piece on Pandora and Groupon for the weekend; but it will...
Clorox is trading at new all time highs today with the help of a nice bump in trade.  The...
Spot Gold has hurdled-- and is sustaining above-- its prior significant rally peak at $130...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.